Literature DB >> 17881399

Long-term survival of patients with multiple sclerosis in West France.

E Leray1, S P Morrissey, J Yaouanq, M Coustans, E Le Page, J Chaperon, G Edan.   

Abstract

In France no data have been published about comparing survival in multiple sclerosis (MS) patients with the general French population. We estimated survival probabilities in MS patients from a major centre for MS in West France. We also compared MS survival with the general population and assessed prognostic parameters. All patients with MS onset after January 1976 and classified as dead or alive on 1 January 2004 were included. One thousand eight-hundred and seventy-nine patients (sex ratio W: M 2.3; relapsing/progressive onset 77.4%/22.6%) fulfilled these criteria, disease duration ranged from one to 28 years. By 2004, 68 patients died (51 due to MS) and the 15 and 25-year survival probabilities were 96% and 88%. Male gender, progressive course (either primary or secondary), polysymptomatic onset, and increased annual relapse rate during the first two years of MS were related to a worse prognosis. After a mean follow-up duration of 12.7 years since clinical onset, MS increased the number of deaths compared with the general population. However taking into account disability status, we found that less disabled MS patients had a better survival and highly disabled patients a worse survival (eight-fold increase of mortality) compared with the French population.

Entities:  

Mesh:

Year:  2007        PMID: 17881399     DOI: 10.1177/1352458507077410

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  19 in total

Review 1.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

2.  Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS.

Authors:  Amber Salter; Tuula Tyry; Guoqiao Wang; Robert J Fox; Gary Cutter; Ruth Ann Marrie
Journal:  Neurol Clin Pract       Date:  2016-10

Review 3.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

4.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

5.  Validity and Reliability of the Turkish Version of the Monitoring My Multiple Sclerosis Scale.

Authors:  Cansu Polat; Zeliha Tülek; Murat Kürtüncü; Mefkure Eraksoy
Journal:  Noro Psikiyatr Ars       Date:  2017-01-19       Impact factor: 1.339

6.  Evidence for a two-stage disability progression in multiple sclerosis.

Authors:  Emmanuelle Leray; Jacqueline Yaouanq; Emmanuelle Le Page; Marc Coustans; David Laplaud; Joël Oger; Gilles Edan
Journal:  Brain       Date:  2010-04-27       Impact factor: 13.501

7.  Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran.

Authors:  Seyed Mohammad Masood Hojjati; Seyyed Ali Hojjati; Mobina Baes; Ali Bijani
Journal:  Caspian J Intern Med       Date:  2014

8.  Predictors of Mortality in Veterans with Multiple Sclerosis in an Outpatient Clinic Setting.

Authors:  Meheroz H Rabadi; Christopher E Aston
Journal:  Int J MS Care       Date:  2017 Sep-Oct

9.  Validity and Reliability of the Turkish Version of the Multiple Sclerosis-Related Symptom Checklist.

Authors:  Zeliha Tülek; Cansu Polat; Murat Kürtüncü; Mefkure Eraksoy
Journal:  Noro Psikiyatr Ars       Date:  2016-04-26       Impact factor: 1.339

Review 10.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.